Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
20121~0
Case MBUS 1040
I~PROV~HæNTS IN C~EHICAL COHPOUNDS
This invention concerns improvements in chemical
compounds, especially in the form of pharmaceutical compositions.
More particularly it concerns compositions and compounds having
activity in ln vitro tests on Human Immunodeficiency Virus-infected
cells.
The disease known as Acquired Immune Deficiency Syndrome
(AIDS~ caused by infection by HIV has attracted immense research
effort because of the effects of the disease on infected
individuals and the dangers of the disease spreading to a wider
section of the population. In general, although various
chemo-therapeutic treatments have been advocated, and some
- 2 - 2 0 ~ 2 1 5 0
compounds have emerged as a potential basis for treatment, there
is still a need for alternatives. In particular, most treatments
such as the compound kno~n as AZT have a high toxicity to cells,
and it would be desirable to find compounds which are less toxic.
We have found a group of compounds which show interesting
properties in ln vitro screens of human cells challenged with HIV-1
and~or HIV-2, and are therefore indicated as having potential for
the treatment of AIDS and AIDS Related Complex. Accordingly, the
present invention provides the use of compounds as defined below,
in pharmaceutical compositions for treating HIV-infected patients.
The invention further provides compositions, especially
pharmaceutical compositions comprising such a compound in
combination or association with a carrier, for example a
pharmaceutically acceptable diluent or excipient, for the treatment
of viral infections, especially for HIV-infected patients. The
invention further provides a process for the preparation of a
pharmaceutical composition for the treatment of a patient,
comprising the combination of a compound as defined below with a
pharmaceutically acceptable diluent or excipient, and formulating
said composition into a form suitable for administration to said
patient. The invention may also be defined as the use of such a
compound for the manufacture of a medicament for the treatment of
patients especially ~IV-infected patients. The invention also
provides a method of treatment of a patient, especially an
~IV-infected patient, comprising administering to said patient an
efrective dose of such a compound. It is to be understood that
treatment includes prophylactic treatment of patients at risk, in
- 3 - 20~21~0
view of the protective properties observed. Anti-viral activity
has not been previously reported for the compounds, and activity in
a screen specific to HIV warrants further study of the compounds
for activity against other viral infections. The in~ention may
therefore be considered as encompassing compositions, processes and
methods as described above, for anti-viral treatment.
Cyclam, described in more detail below, and many of its
cyclic amine analogues are generally known and are commercially
available. They have been proposed as therapeutic agents for a
variety of uses, particularly to remove metals from the system of
poisoned mam~als and in combination with metals to act as magnetic
resonance contrast agents, but it is not believed that there is any
commercial use of these compounds. It is also suggested in USP
4,156,683 and GBP 1,304,367 that certain crown-ether-type
compounds, which are mainly bicyclic, have an antiviral activity
against influenza virus.
It has also been reported (Biochem.J.(1987),245,641-647~
that cyclic polyamines act to inhibit the infectivity of a specific
bacteriophage 0X174. The most active compound was a
hexa-azacyclo-octadecane, with the second most active compound
being a triazacyclodecane. The bacteriophages are quite distinct
from viruses that infect mammalian cells.
According to the present invention, an active ingredient
is provided for anti-viral use in mammals, which is a cyclic amine
of 12 to 20 ring members and having 3 to 5 amino nitrogen atoms in
2012150
-- 4 --
the ring, which is optionally substituted on the carbon atoms of
the ring, or a complex thereof with a non-toxic labile metal atom
or complex, or a compound which is a protected form of said amine
or complex.
Preferably, the cyclic amine has 13 to 18 ring members
and 4 amino nitrogen atoms in the ring. Suitable substituents are
selected from halogens, especially chlorine or bromine, -NH2, -OH,
-COOH, ester groups, -CONH2 and alkyl or aryl groups which
themselves may be substituted by the aforementioned substituents.
Alternatively, the cyclic amines are unsubstituted.
When considering as active ingredients, complexes of the
cyclic amines, it is to be understood that "non-toxic'1 complexing
agents are to be considered with respect to the prognosis for the
patient without che therapy. Thus complexes with zinc and nickel
may be preferred; copper and rhodium for example are not especially
suitable.
The invention also includes what may be termed
"prodrugs", that is protected forms of the cyclic amines or
complexes which release the cyclic amine or complex after
administration to a patient. For example, the cyclic amine or
complex may carry a protective group which is split off by
hydrolysis in body fluids, eg in the bloodstream, thus releasing
active cyclic amine or complex.
2012~0
The invention also includes, as would be clear to the
s~illed man, non-toxic acid addition salts of the cyclic amines
etc.
Particular active ingredients are illustrated
hereinafter.
The compounds of the invention were tested in a screen by
the MTT method (J. Virol. Methods 120: 309-321 [1988]). MT-4 cells
(2.5 x 104 /well) were infected with ~IV-1 (HTLV-IIIB) or HIV-2
(LAV-2 ROD) at a concentration of 100 CCIDso and incubated in the
presence of various concentrations of the test compounds, which
were added immediately after infection with the virus. After 5
days culture at 37C in a CO2 incubator, the ~umber of viable cells
was assessed by the MTT (tetrazolium) method. Antiviral activity
and cytotoxicity of the compounds are expressed in the table below
as ED50 (ug/ml) and CDso (ug/ml), respectively. The potential
therapeutic usefulness was assessed by calculating a Selectivity
Index (SI) corresponding to the ratio of CD50 to EDso~ A control
test was performed using the known anti-HrV treatment AZT.
- 6 - 2012150
~BLE
Ca~ d ~ l HIV-2 i
CD5 o ED5 o SI CD5 ED5 o SI
A 146.5 56.6 3 258.1 22.6 11
B 459.6 30.3 lS 487.4 40.4 12
C 334.2 18.8 18 340.8 >S00 <1
D 11.2 0.3 37 20.5 >40 <1
E 3.35 1.3 3 5.06 >8.0 <1
F 3.36 >8.0 <1 6.03 >8.0 <1
G 194.2 6.96 28 218.3 >1000.0 <1
H 46.9 10.6 4 46.9 >100.0 <1
I 432.5 196.99 2 418.8 >1000.0 <1
AZT >1 <O.008 >125 ND ND ND
X 75.3 >250 <0.3 ND ND ND
>250 >250 -1 ND ND ND
Note: ND s Not Determined
Compound A is cyclam
B is 1,4,8,12-tetrazacyclopentadecane
C is 1,4,8,13-tetrazacyclohexadecane. 4HCl
D is 1,5,9,13-tetraza~yclohexadecane
E is 1,5,9,14-tetrazacycloheptadecane
F is 1,4,7,10,13-pentazacyclopentadecane
G is Zn complex of 1,4,8,12-tetrazacyclopentadecane (Cl-)
H is Zn complex of 1,5,9,13-tetrazacyclohexadecane (Cl-)
I is 5,5,7,12,12,14-hexamethyl-cyclam
X is [Cu cyclam]Cl2
Y is c-[Rh cyclam (NO2)2]Cl
20121~0
-- 7 --
It will be seen from the above results that the compounds
of the invention exhibit activity against ~IV in cells, and their
in vitro toxicity is less than that of AZT.
The metals which are relatively less labile in complexes
with cyclam, such as copper and rhodium in the test results above,
and cobalt, demonstrate a significantly lower selectivity, because
of their higher ED50.
In this field of study, it is considered that any
compound exhibiting a Selectivity Index of greater than 5 has the
potential for further study and development.
HIV is one of the most challenging viruses to co~bat, and
the results given above provide an indication of activity
especially against other retroviruses and against other viruses in
general.
The active compounds as defined may be administered in
the form of pharmaceutical compositions formwlated according to
well known principles and incorporating the compound, preferably in
unit dose form, in combination with a pharmaceutically acceptable
diluent or excipient. Such compositions may be in the fonm of
solutions or suspensions for injection, or irrigation or be in
capsule, tablet, dragee, or other solid composition or as a
solution or suspension for oral administration or for~wlated into
pessaries or suppositories or sustained release forms of any of the
above or for implantation. Suitable diluents, carriers, excipients
2012~0
pessaries or suppositories or sustained release forms of any of the
above or for implantation. Suitable diluents, carriers, excipients
and other components of such compositions are known. It may be
desirable also to formulate a composition for topical
administration such as an ointment or cream. The compounds of the
invention may be used, in the form of a composition or alone, and
possibly carried on a finely divided support, as a coating on
devices or articles which in use contact body fluids, to discourage
transmission of viral infections. Examples of devices or articles
to be considered in this aspect of the invention are surgical
devices and gloves and contraceptives such as condoms, and other
items, appliances, wound dressings and coverings, implements etc.
The pharmaceutical compositions according to the
invention may unit dosages of the aCtiJe compound determined in
accordance with conventional pharmacological methods, suitably to
provide active compounds in the dosage range in humans of from 0.1
to 100 mg/Kg body weight per day, in a single dose or in a number
of smaller doses. Preferred dosage ranges are 1 to 30 mg/Kg body
weight per day. Other active compounds may be used in the
compositions or such active compounds or supplemental therapy may
be included in a course of treatment.
